Vigabatrin for refractory partial epilepsy

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 1, 2013, Pages

  Hemming, Karla ^a   Maguire, Melissa J ^b   Hutton, Jane L ^c   Marson, Anthony G ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VIGABATRIN; ANTICONVULSIVE AGENT;

ADD ON THERAPY; CLINICAL OUTCOME; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FATIGUE; FOCAL EPILEPSY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; STATISTICAL BIAS; SYSTEMATIC REVIEW; VISUAL DISORDER; VISUAL FIELD; DRUG RESISTANCE;

ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSIES, PARTIAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIGABATRIN;

MLCS; MLOWN;

EID: 84874795246     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD007302.pub2     Document Type: Review

References (33)

1. Beran RG, Berkovic SF, Buchanan N, Danta G, Mackenzie R, Schapel G, et al.A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure 1996;5:259-65.
2. Bruni J, Guberman A, Vachon L, Desforges C. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure 2000;9:224-32.
3. Dean C, Mosier M, Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999;40:74-82.
4. Dodrill CB, Arnett JL, Sommerville KW, Sussman NW. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995;36(2):164-73.
5. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993;43:2501-7.
6. French JA, Mosier M, Walker S, Sommerville K, Sussman N. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
7. Gram L, Klosterskov P, Dam M. Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology 1985;17:262-6.
8. Grunewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57:1057-63.
9. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia 1986;27:115-20.
10. McKee PJ, Blacklaw J, Friel E, Thompson GG, Gillham RA, Brodie MJ. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?. Epilepsia 1993;34(5):937-43.
11. Rimmer EM, Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 1984;1(8370):189-90.
12. Tartara A, Manni R, Galimberti CA, Hardenberg J, Orwin J, Perucca E. Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia 1986;27:717-23.
13. Tassinari CA, Michelucci R, Ambrosetto G, Salvi F. Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology 1987;44:907-10.
14. Chiron C, Dulac O, Mumford J. Vigabatrin withdrawal randomised study in children. Epilepsy Research 1996;25:209-15.
15. Gilham RA, Blacklaw J, McKee PJ, Brodie MJ. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology 1993;56:1271-5.
16. Provinciali L, Bartolini M, Mari F, Del Pesce M, Ceravolo MG. Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurologica Scandinavica 1996;94:12-8.
17. Reynolds EH, Ring HA, Farr IN, Heller AJ, Elwes RD. Open, double blind and long term study of vigabatrin in chronic epilepsy. Epilepsia 1991;32:530-8.
18. Ring HA, Farr IN, Reynolds EH. Vigabatrin: rational treatment for chronic epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1990;53:1051-5.
19. Zahner B, Stefan H, Blankenhorn V, Kramer G, Richens A, Thumler R, et al.Once-daily versus twice daily vigabatrin: is there a difference? The results of a double blind pilot study. Epilepsia 1999;40:311-5.
20. Cochrane HC, Marson AG, Baker GA, Chadwick DW. Neuropsychological outcomes in randomised controlled trial of antiepileptic drugs. A systematic review of methodology and reporting standards. Epilepsia 1998;39(10):1088-97.
21. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet 1995;346:140-4.
22. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389-99.
23. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314(7075):180-1.
24. Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database of Systematic Reviews 2008, Issue 4. [DOI: 10.1002/14651858.CD001770.pub2]
25. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota:1935-984. Epilepsia 1993;34(3):453-68.
26. Higgins JPT, Green S, editors. The Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3. Chichester, UK: John Wiley and Sons Ltd., 2005.
27. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
28. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313(7066):1169-74.
29. Nicolson A, Leach JP, Chadwick CW, Smith DF. The legacy of vigabatrin in a regional epilepsy clinic. Journal of Neurology, Neurosurgery, and Psychiatry 2002;73:327-9.
30. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
31. Sander JW, Shorvon SD. Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry 1996;61(5):433-43.
32. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion. Journal of Child Neurology 2005;20 Suppl:1-56.
33. Wild JM, Ahn HS, Baulac M, Bursztryn J, Chrion C, Gandolfo E, et al.Vigabatrin and epilepsy: lessons learned. Epilepsia 2007;48:1318-27.